What Do the Data on New and Emerging ATTs Mean to Clinical Practice?

This activity is part of a series

Faculty

Anna D. Burke, MD
Karsten Solheim Chair for Dementia
Director of Alzheimer’s and Memory Disorders Division
Director of Neuropsychiatry
Department of Neurology
Barrow Neurological Institute
Phoenix, AZ
Anna D. Burke, MD

Anna D. Burke, MD, is a board-certified geriatric psychiatrist, the Karsten Solheim Chair for Dementia, and the Director of the Alzheimer’s and Memory Disorders Division at Barrow Neurological Institute in Phoenix, Arizona. She also currently directs the Department of Neuropsychiatry at Barrow Neurological Institute. Barrow Neurological Institute is a world-class neurological and neurosurgical institute with a mission to accept challenges, reject norms, and push boundaries. The Barrow Alzheimer’s and Memory Disorders Division is one of the leading clinical and research institutes in the world, championing research in neurodegenerative disorders.

Dr. Burke has worked extensively with patients and families suffering with neurodegenerative disorders including Alzheimer’s disease (AD). Her area of expertise includes the diagnosis and management of cognitive disorders and the treatment of challenging behavioral and psychiatric disturbances that result from neurological conditions. In addition to her clinical work, she has led the development of comprehensive multispecialty clinical care models focused on improving the quality of care for individuals with cognitive impairment as well as improving the diagnosis and management of AD and related dementias in the community. Dr. Burke is a well-respected researcher, having led over 100 clinical trials of investigational therapies for AD and related dementias, and is a well-respected author and key opinion leader in the field.

Fanny M. Elahi, MD, PhD
Assistant Professor, Icahn School of Medicine at Mount Sinai
Departments of Neurology, Neuroscience, and Pathology
Friedman Brain Institute
Ronald M. Loeb Center for Alzheimer’s Disease
Cardiovascular Research Institute
New York, NY
Fanny M. Elahi, MD, PhD

Fanny Elahi, MD, PhD, is a board-certified physician-scientist and Principal Investigator in the Departments of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai in New York City. Dr. Elahi’s work focuses on the role of the brain’s vascular system as people age, examining the link between small blood vessels and neurodegeneration. She is passionate about translating laboratory discoveries into clinical applications and aims to inspire hope for a cure for Alzheimer’s disease, Parkinson’s disease, and rare genetic disorders such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). For more information about Dr. Elahi, please visit https://www.elahilab.com/.

Statement of Need

Each day matters when it comes to slowing the progression of Alzheimer’s disease (AD), so it is imperative that health care professionals (HCPs) in this field are able to provide optimal care for patients with AD in a timely manner while applying the latest clinical trial data to practice, including the varied safety and efficacy data on new and emerging amyloid-targeting therapies (ATTs). ATTs have been shown to be promising in delaying disease progression in individuals with mild cognitive impairment or early dementia due to AD. To realize the full potential of ATTs, HCPs need education on clinical data of ATT agents in order to appropriately translate that information to improve diagnosis and management of AD.

In this CME Outfitters Snack, expert faculty will review data presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and will focus on established, new, and emerging ATTs as well as a case-based discussion on clinical impacts and applications to provide point-of-care tactics that will have a positive impact on patient outcomes.

Learning Objective

Evaluate clinical practice implications of clinical trial data for established and emerging ATTs.

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

Dementia specialists, neurologists, psychiatrists, neurology and psychiatry nurse practitioners (NPs) and physician associates (PAs), and other clinicians caring for patients with AD in the United States and globally (with the exception of UK-based clinicians)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 12/20/2024. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Burke reports the following financial relationships:

Advisory Board and Consultant: Eisai Inc.; Lilly; and Roche

Dr. Elahi reports the following financial relationships:

Advisory Board: Cordance Medical; cureCADASIL; and Eisai
Inc.

Consultant: Alkahest, Inc.; Cordance Medical; CuraSen Therapeutics, Inc.; and Therini Bio

Research Support: Meso Scale

Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:

  • Jeffrey Helfand, DO (peer reviewer
  • Albert Eubanks, Jr., RN (peer reviewer)
  • Susan Perry (planning committee)
  • Kellie Busby, PharmD, BCPP (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-207-122023-11

What Do the Data on New and Emerging ATTs Mean to Clinical Practice?
Event Date: 12/20/2023 at 12:00 am EST